This comprehensive systematic review and meta-analysis pooled data from 80 population-based studies encompassing more than 260,000 individuals and estimated a global irritable bowel syndrome (IBS) prevalence of 11.2%. However, prevalence varied markedly (1%-45%) depending on geographic region, diagnostic criteria, and study methodology. Rates were lowest in Southeast Asia (7%) and highest in South America (21%). Diagnostic framework substantially influenced estimates, ranging from 8.8% with Rome I criteria to 14% using Manning criteria. Prevalence was generally higher when symptoms were self-reported through questionnaires rather than interviewer-administered, and when shorter minimum symptom-duration thresholds (e.g., 3 months vs 12 months) were applied. Among IBS subtypes, IBS-D was frequently the most common pattern reported, although studies including IBS-U demonstrated a more balanced distribution across IBS-C, IBS-D, IBS-M, and IBS-U.

Women had a significantly higher likelihood of IBS than men (OR 1.67; 95% CI, 1.53-1.82), while individuals aged ≥50 years had lower odds compared with younger adults (OR 0.75; 95% CI, 0.62-0.92). Socioeconomic status did not show a consistent association with prevalence, although few studies reported these data. Despite substantial heterogeneity across studies, the findings underscore IBS as a prevalent, globally distributed disorder associated with meaningful quality-of-life impairment and economic burden. Variability by geography, methodology, and diagnostic criteria highlights the importance of standardized definitions and the need for additional research in underrepresented regions.

Reference: Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4. doi:10.1016/j.cgh.2012.02.029. PMID: 22426087.

Irritable bowel syndrome (IBS) is a common functional GI disorder characterized by abdominal pain/discomfort and altered bowel habits without structural or biochemical abnormalities. Its cause is uncertain and likely multifactorial, with psychosocial factors (stress, anxiety/depression, trauma history) often coexisting and amplifying symptoms via the brain–gut axis—contributing to variability and overlap with other functional somatic syndromes (e.g., fibromyalgia, chronic fatigue).

This review emphasizes symptom-based diagnosis using established criteria (Manning/Kruis/Rome, commonly Rome III) while avoiding extensive testing in younger patients without alarm features. Targeted evaluation is reserved for red flags, older patients, and celiac testing in non-constipating IBS. Management is individualized and multimodal: build a strong clinician–patient relationship; address diet/lifestyle (selective elimination diets/FODMAP considerations, soluble fiber like psyllium), exercise, and stress reduction; consider CBT or hypnotherapy; and tailor medications to dominant symptoms (antispasmodics/peppermint oil for pain, TCAs/SSRIs for global symptoms, PEG/secretagogues for IBS-C, loperamide for diarrhea, and alosetron for severe IBS-D with careful risk management). The authors note high placebo response rates and mixed evidence—especially for CAM/probiotics—while highlighting ongoing development of therapies targeting specific mechanisms.

Reference: Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014 Jun 14;20(22):6759-73. doi: 10.3748/wjg.v20.i22.6759. PMID: 24944467; PMCID: PMC4051916.

In a nationwide US survey of more than 70,000 adults, researchers compared how often and how severely lower and upper GI symptoms occur in irritable bowel syndrome with constipation (IBS-C) versus chronic idiopathic constipation (CIC). Adults (≥18 years) completed the NIH GI-PROMIS questionnaire, which uses validated scores to capture symptom frequency and intensity over the prior 7 days. The final analytic sample included 970 eligible respondents (275 IBS-C; 734 CIC). Investigators compared symptom prevalence using adjusted odds ratios and evaluated group differences in PROMIS scores, controlling for demographic differences.

Overall symptom burden was higher in IBS-C than CIC, with significantly higher adjusted global GI-PROMIS scores (251.1 vs 177.8; P<0.001). Abdominal pain stood out as a key differentiator—more common (OR 4.3) and more severe in IBS-C—while constipation severity was also modestly higher in IBS-C. Incontinence was more frequent in IBS-C (OR 2.9) but not more severe. Upper GI symptoms (dysphagia, heartburn, nausea) were similarly prevalent across groups, although heartburn severity was greater in IBS-C. The authors conclude that IBS-C generally has a more severe symptom profile than CIC, but CIC still commonly includes abdominal pain, bloating, and upper GI symptoms.

Reference: Shah ED, Almario CV, Spiegel BMR, Chey WD. Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. J Neurogastroenterol Motil. 2018 Apr 30;24(2):299-306. doi: 10.5056/jnm17112. PMID: 29605985; PMCID: PMC5885729.

Authors of a scoping review of 27 clinical practice guidelines (CPGs) from 2012 to 2024 found considerable inconsistency in diagnostic criteria for constipation-predominant IBS (IBS-C) and functional constipation (FC). Rome IV was most commonly used (59.3%), followed by Rome III (22.2%). IBS-C guidelines emphasized abdominal pain (71.4%), whereas FC guidelines prioritized spontaneous bowel movement frequency (88.9%). IBS-C CPGs often endorsed positive, symptom-based diagnosis (71.4%) versus far fewer FC CPGs (11.1%). Forty percent of CPGs acknowledged overlap between IBS-C and FC. One guideline proposed a pain threshold (Likert >4) to define “painful constipation.” Regional variation was notable: some Asian-based CPGs highlighted Bristol Stool Form Scale type 3 and abdominal bloating; most CPGs (81.5%) recommended colonoscopy only for alarm features or age criteria. These discrepancies likely skew prevalence estimates, payer policies, and clinical trial eligibility across regions.

Overall, the landscape is fragmented and region-dependent, complicating differential diagnosis and care pathways. The authors call for harmonized criteria that better integrate both pain and constipation domains across IBS-C and FC, and for progress toward objective biomarkers to reduce reliance on symptoms alone. As an interim step, standardized reporting of stool form, pain intensity scales, and symptom duration could improve comparability across settings while biomarker research matures.

Reference: Luo J, To WLW, Xu Q, et al. Clinical practice guidelines for the diagnosis of constipation-predominant irritable bowel syndrome and functional constipation in adults: a scoping review. BMC Gastroenterol. 2025;25(1):234. doi: 10.1186/s12876-025-03774-6.

Chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) produce overlapping symptoms—constipation, bloating/distension, and pain—likely along a spectrum where pain/hypersensitivity is more prominent in IBS-C. Both conditions carry heavy quality-of-life impacts and common comorbidities, though profiles differ (CIC: diabetes/obesity; IBS-C: anxiety/depression, functional dyspepsia, fibromyalgia, interstitial cystitis). BURDEN studies show a wide patient-clinician perception gap and low satisfaction with care: many patients rely on over-the-counter (OTC) medications, few feel in control, and stigma or uncertainty keeps many from seeking help or receiving a firm diagnosis—fueling unnecessary tests and anxiety.

The economic and treatment burdens are substantial: frequent outpatient visits, high use of imaging/colonoscopy despite limited diagnostic yield, and insurer hurdles. Most patients self-manage with OTCs. Prescription uptake is low, and treatment-emergent diarrhea is a frequent reason for discontinuation. Sex and cultural factors shape illness experience and care-seeking (eg, lower health-related quality of lfie and more bloating in women; variable healthcare use by sex and ethnicity). Because CIC and IBS-C often overlap and fluctuate, management should be individualized and patient-centric, which includes aligning on diagnosis and goals, addressing comorbidities and psychosocial drivers, tailoring therapy to the most bothersome symptoms, using prescriptions when indicated, avoiding low-value testing, and planning for adverse-event management to improve outcomes and reduce social/economic burden.

Reference: Harris LA, Chang CH. Burden of Constipation: Looking Beyond Bowel Movements. Am J Gastroenterol. 2022;117(4S):S2-S5. doi: 10.14309/ajg.0000000000001708.

Abdominal bloating and distension are common, often debilitating symptoms affecting up to 90% of irritable bowel syndrome (IBS) patients and about one-third of the general population. Bloating refers to a subjective sensation of gassiness or pressure, while distension is an objective increase in abdominal girth. These symptoms, especially prevalent in women and patients with IBS with constipation, can significantly impair quality of life. Their causes are multifactorial—ranging from small intestinal bacterial overgrowth, carbohydrate intolerance, and celiac disease to disorders of gut-brain interaction, altered motility, pelvic floor dysfunction, and abdominophrenic dyssynergia. Diagnosis relies on detailed history, physical exam, and targeted testing such as breath tests, imaging, and motility studies.

Treatment must be individualized and multifaceted. Dietary interventions, particularly low-FODMAP diets, are often first-line approaches. Depending on the cause, probiotics, rifaximin, secretagogues, prokinetics, or antispasmodics may help. Neuromodulators, biofeedback, and hypnotherapy are effective in patients with visceral hypersensitivity or abnormal reflexes. Complementary therapies like peppermint oil can also provide relief. Ultimately, managing bloating and distension requires identifying key contributing factors and engaging patients in shared decision-making to tailor safe, effective, and sustainable treatments.

Reference: Lacy BE, Cangemi D, Vazquez-Roque M. Management of Chronic Abdominal Distension and Bloating. Clin Gastroenterol Hepatol. 2021 Feb;19(2):219-231.e1. doi: 10.1016/j.cgh.2020.03.056. Epub 2020 Apr 1. PMID: 32246999.

In this patient case study, JP, a 24-year-old male, presents with a yearlong history of lower abdominal pain, bloating, and infrequent, difficult-to-evacuate stools, following a stressful trip during which he experienced personal turmoil and restroom access issues. Given the chronicity, normal lab results (complete blood count [CBC], metabolic profile, thyroid tests, C-reactive protein [CRP], celiac serologies), and normal colonoscopy, JP meets the Rome IV diagnostic criteria for irritable bowel syndrome with constipation (IBS-C). Importantly, his history lacks alarm features such as significant weight loss, bleeding, or nocturnal symptoms, suggesting no serious underlying organic disease.

IBS-C is chronic, often persisting for many years if untreated, negatively impacting quality of life but not lifespan or cancer risk. Excessive diagnostic testing beyond initial screening (CBC, CRP, celiac serologies) is generally unnecessary and can lead to anxiety and unnecessary procedures. Dietary adjustments, such as increased fiber or low-FODMAP diets, offer limited benefits for IBS-C specifically. Instead, treatment typically involves FDA-approved medications like lubiprostone, linaclotide, plecanatide (secretagogues), or tenapanor (retainagogue), all of which target abdominal pain, stool consistency, and bowel frequency effectively. Patients should be advised of potential side effects, predominantly diarrhea, and understand that treatment response can occur quickly for constipation but more slowly for abdominal symptoms.

Reference: Lacy BE. Managing IBS-C: Focus on Symptom Control. Gastroenterol Hepatol (NY). 2024 Apr;20(4):216-226. PMID: 38682119; PMCID: PMC11047151.

To diagnose irritable bowel syndrome (IBS), doctors typically review a patient's symptoms, medical and family history, and perform a physical exam. A key part of the diagnosis involves identifying patterns in symptoms, such as abdominal pain linked to bowel movements, changes in stool frequency, and stool appearance. The doctor may diagnose IBS if symptoms have been present at least once a week for the past three months and first started at least six months ago. Additional symptoms such as anemia, rectal bleeding, bloody stools, or weight loss may suggest another condition rather than IBS. During a physical exam, doctors check for abdominal bloating, listen to abdominal sounds, and tap the abdomen to check for tenderness.

While IBS is generally diagnosed based on symptoms, doctors may order tests to rule out other health problems. Blood tests can check for anemia, infection, or other digestive diseases, while stool tests help detect blood or infections. Additional tests, such as a hydrogen breath test, upper gastrointestinal endoscopy, or colonoscopy, may be used if there are concerns about other conditions like small intestinal bacterial overgrowth, celiac disease, or colon cancer. These tests help ensure that IBS is the correct diagnosis and rule out any other potential causes for the symptoms.

Reference: Diagnosis of Irritable Bowel Syndrome. NIDDK. Updated November 2017. Accessed February 7, 2025. https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/diagnosis

In this large-scale, multinational study involving 73,076 adults across 33 countries, the global prevalence of functional gastrointestinal disorders (FGIDs) was found to be substantial. Specifically, 40.3% of internet survey respondents and 20.7% of household survey respondents met diagnostic criteria for at least one FGID. Women consistently reported higher prevalence rates than men. FGIDs were linked to significantly decreased quality of life and increased healthcare utilization, highlighting their considerable impact on both individuals and healthcare systems worldwide.

Additionally, this research revealed that the updated Rome IV criteria identified fewer irritable bowel syndrome cases compared to the older Rome III criteria, suggesting stricter diagnostic standards. Despite variations in absolute prevalence between internet-based and in-person data collection methods, consistent trends in demographics, health impacts, and symptom distribution were observed. These findings underscore the global burden of FGIDs and support continued research and healthcare planning tailored to addressing these widespread conditions.

Reference: Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021 Jan;160(1):99-114.e3. doi: 10.1053/j.gastro.2020.04.014. Epub 2020 Apr 12. PMID: 32294476.

This nationwide, population-based study used data from the National GI Survey to evaluate abdominal pain characteristics across irritable bowel syndrome (IBS) subtypes using the validated GI-PROMIS instrument. Of the 71,812 survey participants, 1,158 met modified Rome III criteria for IBS and reported abdominal pain within the past 7 days. These participants were stratified into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed bowel habits (IBS-M) groups. Compared to IBS-D, individuals with IBS-C reported significantly more bothersome, frequent, and interfering abdominal pain. IBS-C and IBS-M also showed more diffuse pain patterns and involvement of a greater number of abdominal regions. IBS-C had the highest composite GI-PROMIS scores, indicating greater pain burden.

The study highlights that abdominal pain manifests differently across IBS subtypes, with patients with IBS-C experiencing the most severe and diffuse symptoms. These differences may reflect distinct underlying mechanisms, including variations in visceral hypersensitivity and neural pain processing. The findings suggest that abdominal and bowel symptoms differ not only in frequency but in qualitative experience across subtypes, potentially supporting a move toward subtype-specific management strategies. Limitations included lack of medication and mood disorder assessments, but strengths included use of a validated, symptom-specific tool and a nationally representative cohort.

Reference: Shah ED, Almario CV, Spiegel BM, et al. Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study. Am J Gastroenterol. 2020 Feb;115(2):294-301. doi: 10.14309/ajg.0000000000000502. PMID: 31913193; PMCID: PMC7469977.

This study aimed to explore the prevalence and types of functional gastrointestinal disorders (FGIDs) in patients with eating disorders (EDs) such as anorexia nervosa (AN), bulimia nervosa (BN), and eating disorders not otherwise specified (EDNOS). It also sought to identify predictors of these disorders. A total of 101 female patients, with a mean age of 21 years, completed the Rome II modular questionnaire and other validated self-reported assessments. The results showed that 98% of participants met the criteria for at least one FGID, with the most common being irritable bowel syndrome (IBS), functional heartburn, functional abdominal bloating, and functional constipation. Over half of the sample had at least three coexisting FGIDs.

Psychological factors, including somatization, neuroticism, and anxiety, as well as age and binge eating, were significant predictors of specific FGID types and the presence of multiple coexisting FGIDs. Interestingly, other disordered eating factors, such as body mass index, were not predictive. The study concluded that specific psychological traits play a key role in the development of certain FGIDs in patients with eating disorders, suggesting that addressing these psychological factors may help in managing gastrointestinal symptoms in this population.

Reference: Boyd C, Abraham S, Kellow J. Psychological features are important predictors of functional gastrointestinal disorders in patients with eating disorders. Scand J Gastroenterol. 2005 Aug;40(8):929-35. doi: 10.1080/00365520510015836. PMID: 16170899.

This study aimed to compare pelvic floor symptoms, such as pelvic organ prolapse (POP) and lower urinary tract symptoms (LUTS), between patients with irritable bowel syndrome with constipation (IBS-C) and functional constipation (FC). It also examined their correlation with anorectal manometry (ARM) findings. The researchers used the Pelvic Floor Distress Inventory (PFDI-20) to assess pelvic floor distress and the Constipation Severity Scale to measure the severity of constipation. A total of 107 patients (64 with FC and 43 with IBS-C) participated in the analysis.

The study found that patients with IBS-C experienced higher levels of distress from POP, LUTS, and colorectal symptoms compared to those with FC. Multivariable regression analysis showed that IBS-C and higher constipation severity were independently associated with higher PFDI-20 scores. However, no correlation was found between ARM parameters, abnormal balloon expulsion tests, and PFDI scores. These results suggest that patients with IBS-C experience greater pelvic floor symptom distress than FC patients The severity of constipation also plays a role in this distress, although dyssynergia (abnormal anorectal function) did not contribute to the findings.

Reference: Singh P, Seo Y, Ballou S, et al. Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia. J Neurogastroenterol Motil. 2019 Jan 31;25(1):129-136. doi: 10.5056/jnm17139. PMID: 30646484; PMCID: PMC6326213.